JLE

Médecine thérapeutique

MENU

Neuropathies périphériques et gammapathies monoclonales Volume 24, numéro 5, Septembre-Octobre 2018

  • [1] Mrouki M., Ben Salem T., Said F. Profil étiologique des neuropathies périphériques en médecine interne. Rev Med Interne. 2014;35S:A144.
  • [2] Kelly J.J., Kyle R.A., O’Brien P.C., Dyck P.J. Prevalence of monoclonal protein in peripheral neuropathy. Neurology. 1981;31:1480-1483.
  • [3] Steiner N., Schwärzler A., Göbel G., Löscher W., Wanschitz J., Gunsilius E. Are neurological complications of monoclonal gammopathy of undetermined significance underestimated? Oncotarget. 2017;8:5081-5091.
  • [4] Chaudhry H.M., Mauermann M.L., Rajkumar S.V. Monoclonal gammopathy-associated peripheral neuropathy: diagnosis and management. Mayo Clin Proc. 2017;92:838-850.
  • [5] Gregersen H., Vangsted A.J., Abildgaard N. The impact of comorbidity on mortality in multiple myeloma: a Danish nationwide population-based study. Cancer Medicine. 2017;6:1807-1816.
  • [6] Terret C., Albrand G., Rainfray M., Soubeyran P. Impact of comorbidities on the treatment of non-Hodgkin's lymphoma: a systematic review. Expert Rev Hematol. 2015;8:329-341.
  • [7] Bida J.P., Kyle R.A., Therneau T.M. Disease associations with monoclonal gammopathy of undetermined significance: a population-based study of 17,398 patients. Mayo Clin Proc. 2009;84:685-693.
  • [8] Ramchandren S., Lewis R.A. An update on monoclonal gammopathy and neuropathy. Curr Neurol Neurosci Rep. 2012;12:102-110.
  • [9] Ilyas A., Gu Y., Dalakas M.C., Quarles R.H., Bhatt S. Induction of experimental ataxic sensory neuronopathy in cats by immunization with purified SGPG. J Neuroimmunol. 2008;193:87-93.
  • [10] Herrendorff R., Hänggi P., Pfister H. Selective removal of pathogenic anti-MAG autoantibodies, an antigen-specific treatment option for anti-MAG neuropathy. Proc Natl Acad Sci U S A. 2017;114:3689-3698. in vivo
  • [11] Treon S.P., Hunter Z.R., Castillo J.J., Merlini G. Waldenström macroglobulinemia. Hematol Oncol Clin North Am. 2014;28:945-970.
  • [12] Mohty M., Mohty B., El-Cheikh J., Yakoub-Agha I., Moreau P. Neuropathie périphérique et nouvelles thérapeutiques du myélome multiple : état des lieux et recommandations pratiques. Corresp Onco-hematol. 2008;3:187-195.
  • [13] Lalive P.H., Kuntzer T., Dietrich P.Y. Neuropathies associées aux paraprotéinémies (gammapathies monoclonales). Rev Med Suisse. 2013;9:929-933.